These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6339571)
1. Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis. Kang K; Cooper KD; Hanifin JM J Am Acad Dermatol; 1983 Mar; 8(3):372-7. PubMed ID: 6339571 [TBL] [Abstract][Full Text] [Related]
2. FcIgG receptor-bearing lymphocytes and monoclonal antibody-defined T cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5). Strannegård O; Strannegård IL; Kang K; Cooper KD; Hanifin JM Int Arch Allergy Appl Immunol; 1982; 69(3):238-44. PubMed ID: 6752042 [TBL] [Abstract][Full Text] [Related]
3. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets. Cooper KD; Kang K; Hanifin JM Diagn Immunol; 1983; 1(3):211-5. PubMed ID: 6388971 [TBL] [Abstract][Full Text] [Related]
4. Suppressor cell phenotype deficiency and its restoration by thymopoietin pentapeptide in atopic dermatitis. Kang K; Strannegård O; Strannegård IL; Cooper K; Hanifin JM Monogr Allergy; 1983; 18():181-5. PubMed ID: 6227816 [No Abstract] [Full Text] [Related]
6. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies. Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238 [No Abstract] [Full Text] [Related]
7. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies. Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507 [TBL] [Abstract][Full Text] [Related]
8. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function. Joffe MI; Sochett E; Pettifor JM; Rabson AR J Clin Lab Immunol; 1982 May; 8(1):69-73. PubMed ID: 6212686 [TBL] [Abstract][Full Text] [Related]
9. Thymopoietin pentapeptide treatment of primary immunodeficiencies. Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256 [TBL] [Abstract][Full Text] [Related]
10. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency. Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide]. Djawari D; Bolla K; Haneke E Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167 [TBL] [Abstract][Full Text] [Related]
12. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients. Przybilla B; Burg G; Schmoeckel C; Braun-Falco O Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843 [TBL] [Abstract][Full Text] [Related]
13. Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis. Veys EM; Huskisson EC; Rosenthal M; Vischer TL; Mielants H; Thrower PA; Scott J; Ott H; Scheijgrond H; Symoens J Ann Rheum Dis; 1982 Oct; 41(5):441-3. PubMed ID: 6751241 [TBL] [Abstract][Full Text] [Related]
14. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome. Hamilton G; Zöch G; Rath T; Meissl G Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748 [No Abstract] [Full Text] [Related]
15. Bone marrow transplantation and thymopoietin pentapeptide treatment in two infants with immunodeficiency with predominant T-cell defects. Businco L; Rossi P; Paganelli R; Galli E; DiGilio G; Lulli P; Aiuti F Clin Immunol Immunopathol; 1984 Oct; 33(1):123-30. PubMed ID: 6383671 [TBL] [Abstract][Full Text] [Related]
16. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients. Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382 [No Abstract] [Full Text] [Related]
17. Thymopentin (TP-5) in the treatment of rheumatoid arthritis. Kantharia BK; Goulding NJ; Hall ND; Davies J; Maddison PJ; Bacon PA; Farr M; Wojtulewski JA; Englehart KM; Liyanage SP Br J Rheumatol; 1989 Apr; 28(2):118-23. PubMed ID: 2650797 [TBL] [Abstract][Full Text] [Related]
18. Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study. Malaise MG; Hauwaert C; Franchimont P; Danneskiold-Samsoe B; Bach-Andersen R; Gross D; Gerber H; Gerschpacher H; Stocker H; Bolla K Lancet; 1985 Apr; 1(8433):832-6. PubMed ID: 2858708 [TBL] [Abstract][Full Text] [Related]
19. [Model for acquired immunodeficiency caused by anesthesia and surgical procedures. Effect of treatment with thymopoietin pentapeptide (TP5)]. Auteri A; D'Aniello C; Falotico N; Saletti M; Di Perri T Recenti Prog Med; 1986 Sep; 77(9):423-8. PubMed ID: 3541085 [No Abstract] [Full Text] [Related]
20. A prospective study of thymopentin in severely burned patients. Waymack JP; Jenkins M; Warden GD; Solomkin J; Law E; Hummel R; Miller A; Alexander JW Surg Gynecol Obstet; 1987 May; 164(5):423-30. PubMed ID: 3554564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]